TLSA — Tiziana Life Sciences Share News
0.000.00%
Last trade - 00:00- $137.84m
- $134.28m
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study
Brief: Tiziana Life Sciences Doses First Patient In Phase 2 Alzheimer’S Clinical Trial
Brief: Tiziana Life Sciences Announces Withdrawal Of Proposed Public Offering
Brief: Aquestive Therapeutics Announces Leadership Expansion To Support Growth
Brief: Department Of Defense Awards Grant To Advance Tiziana’s Intranasal Anti-CD3 Therapy for Treating Spinal Cord Injury
Brief: Tiziana Life Sciences Executive Chairman Gabriele Cerrone Purchased 15,000 Common Shares At $1.55 Per Share
Brief: Tiziana Life Sciences Announces University of Massachusetts Starts Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Brief: Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab In Phase 2 Multiple Sclerosis Clinical Trial
Brief: Tiziana Life Sciences Ltd Files For Mixed Shelf Of Up To $250 Million - SEC Filing
Brief: Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial
Brief: Tiziana Life Sciences Announces Agreement With Renaissance Lakewood
Brief: Tiziana Life Sciences Announces Agreement For Product Development Services With Renaissance Lakewood, Llc
Brief: Tiziana Announces Discovery Of New Immune Biomarkers In Multiple Sclerosis Patients Treated With Nasal Foralumab
Brief: Tiziana Announces Reduction Of Side Effects Commonly Seen With Discontinuation Of GLP-1 Agonists With Nasal Anti-CD3
Brief: Tiziana Life Sciences Announces Registered Direct Offering Of About $10 Mln
Brief: Tiziana Life Sciences Announces Positive Results From Ozempic And Nasal Anti-CD3 Combination Study